drugset / Trial / NCT06483737

Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)

NCT06483737

RandomizedParallel-groupOpen-labelTreatment

Summary

Hepatic encephalopathy (HE), a severe complication of decompensated cirrhosis, is characterized as neurocognitive dysfunction. Emerging evidence suggests the potential role of human albumin infusion for the treatment of HE, but its optimal dosage remains undefined. Therefore, the investigators planned a randomized controlled trial (RCT) to compare the efficacy of human albumin infusion at different dosages in in patients with liver cirrhosis and overt HE.

Timeline

Start
2025-06-24
Primary completion
2027-06-30
Completion
2027-06-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Albumin Protein / enzyme biologic 10 g Intravenous
Subject Albumin Protein / enzyme biologic 20 g Intravenous
Subject Albumin Protein / enzyme biologic 30 g Intravenous
Subject Albumin Protein / enzyme biologic 60 g Intravenous
Background Branched-Chain Amino Acids Other / unclassified
Background L-arginine Small molecule
Background L-ornithine L-aspartate Other / unclassified
Background Lactulose Other / unclassified
Background Rifaximin Other / unclassified